#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Protocols to Induce Mature EC Phenotype
1-1	0-2	3.	_	_	_	_
1-2	3-12	Protocols	abstract	new	coref	4-16[22_0]
1-3	13-15	to	_	_	_	_
1-4	16-22	Induce	_	_	_	_
1-5	23-29	Mature	abstract[3]	new[3]	ana	2-1[0_3]
1-6	30-32	EC	organization|abstract[3]	new|new[3]	coref	16-10
1-7	33-42	Phenotype	abstract[3]	new[3]	_	_

#Text=It is well known that for clinical use , it is mandatory to generate cells able to show a high degree of commitment .
2-1	43-45	It	abstract	giv	_	_
2-2	46-48	is	_	_	_	_
2-3	49-53	well	_	_	_	_
2-4	54-59	known	_	_	_	_
2-5	60-64	that	_	_	_	_
2-6	65-68	for	_	_	_	_
2-7	69-77	clinical	abstract[5]	new[5]	_	_
2-8	78-81	use	abstract[5]	new[5]	_	_
2-9	82-83	,	_	_	_	_
2-10	84-86	it	abstract	new	cata	2-10[0_7]
2-11	87-89	is	_	_	_	_
2-12	90-99	mandatory	_	_	_	_
2-13	100-102	to	abstract[7]	new[7]	_	_
2-14	103-111	generate	abstract[7]	new[7]	_	_
2-15	112-117	cells	abstract[7]|object	new[7]|new	ana	4-20
2-16	118-122	able	abstract[7]	new[7]	_	_
2-17	123-125	to	abstract[7]	new[7]	_	_
2-18	126-130	show	abstract[7]	new[7]	_	_
2-19	131-132	a	abstract[7]|abstract[9]	new[7]|new[9]	_	_
2-20	133-137	high	abstract[7]|abstract[9]	new[7]|new[9]	_	_
2-21	138-144	degree	abstract[7]|abstract[9]	new[7]|new[9]	_	_
2-22	145-147	of	abstract[7]|abstract[9]	new[7]|new[9]	_	_
2-23	148-158	commitment	abstract[7]|abstract[9]|abstract	new[7]|new[9]|new	_	_
2-24	159-160	.	_	_	_	_

#Text=This requirement fulfills not only functional issues , but also safety ones , in order to prevent teratoma formation after implantation .
3-1	161-165	This	abstract[11]	new[11]	_	_
3-2	166-177	requirement	abstract[11]	new[11]	_	_
3-3	178-186	fulfills	_	_	_	_
3-4	187-190	not	_	_	_	_
3-5	191-195	only	abstract[12]	new[12]	_	_
3-6	196-206	functional	abstract[12]	new[12]	_	_
3-7	207-213	issues	abstract[12]	new[12]	_	_
3-8	214-215	,	_	_	_	_
3-9	216-219	but	_	_	_	_
3-10	220-224	also	_	_	_	_
3-11	225-231	safety	abstract|object[14]	new|new[14]	coref|coref	27-9[185_14]|27-9[185_14]
3-12	232-236	ones	object[14]	new[14]	_	_
3-13	237-238	,	_	_	_	_
3-14	239-241	in	_	_	_	_
3-15	242-247	order	_	_	_	_
3-16	248-250	to	_	_	_	_
3-17	251-258	prevent	_	_	_	_
3-18	259-267	teratoma	abstract|event[16]	new|new[16]	_	_
3-19	268-277	formation	event[16]	new[16]	_	_
3-20	278-283	after	event[16]	new[16]	_	_
3-21	284-296	implantation	event[16]|event	new[16]|new	_	_
3-22	297-298	.	_	_	_	_

#Text=Thus , a prerequisite to exploit iPSC-ECs in the clinical setting is the development of defined protocols to guide their differentiation into functional endothelial cells .
4-1	299-303	Thus	_	_	_	_
4-2	304-305	,	_	_	_	_
4-3	306-307	a	abstract[18]	new[18]	coref	4-13[21_18]
4-4	308-320	prerequisite	abstract[18]	new[18]	_	_
4-5	321-323	to	_	_	_	_
4-6	324-331	exploit	_	_	_	_
4-7	332-340	iPSC-ECs	object	new	_	_
4-8	341-343	in	_	_	_	_
4-9	344-347	the	time[20]	new[20]	_	_
4-10	348-356	clinical	time[20]	new[20]	_	_
4-11	357-364	setting	time[20]	new[20]	_	_
4-12	365-367	is	_	_	_	_
4-13	368-371	the	abstract[21]	giv[21]	coref	18-8[120_21]
4-14	372-383	development	abstract[21]	giv[21]	_	_
4-15	384-386	of	abstract[21]	giv[21]	_	_
4-16	387-394	defined	abstract[21]|abstract[22]	giv[21]|giv[22]	coref	16-4[94_22]
4-17	395-404	protocols	abstract[21]|abstract[22]	giv[21]|giv[22]	_	_
4-18	405-407	to	_	_	_	_
4-19	408-413	guide	_	_	_	_
4-20	414-419	their	object|event[24]	giv|new[24]	coref|coref|coref|coref	4-23[26_0]|6-12[37_24]|4-23[26_0]|6-12[37_24]
4-21	420-435	differentiation	event[24]	new[24]	_	_
4-22	436-440	into	_	_	_	_
4-23	441-451	functional	object[26]	giv[26]	coref	5-24[30_26]
4-24	452-463	endothelial	object|object[26]	new|giv[26]	_	_
4-25	464-469	cells	object[26]	giv[26]	_	_
4-26	470-471	.	_	_	_	_

#Text=The ideal induction protocol should be reproducible , easy to perform and relatively quick in order to allow yielding an adequate quantity of homogeneous cells .
5-1	472-475	The	abstract[28]	new[28]	coref	24-4[165_28]
5-2	476-481	ideal	abstract[28]	new[28]	_	_
5-3	482-491	induction	abstract|abstract[28]	new|new[28]	coref	6-2
5-4	492-500	protocol	abstract[28]	new[28]	_	_
5-5	501-507	should	_	_	_	_
5-6	508-510	be	_	_	_	_
5-7	511-523	reproducible	_	_	_	_
5-8	524-525	,	_	_	_	_
5-9	526-530	easy	_	_	_	_
5-10	531-533	to	_	_	_	_
5-11	534-541	perform	_	_	_	_
5-12	542-545	and	_	_	_	_
5-13	546-556	relatively	_	_	_	_
5-14	557-562	quick	_	_	_	_
5-15	563-565	in	_	_	_	_
5-16	566-571	order	_	_	_	_
5-17	572-574	to	_	_	_	_
5-18	575-580	allow	_	_	_	_
5-19	581-589	yielding	_	_	_	_
5-20	590-592	an	quantity[29]	new[29]	_	_
5-21	593-601	adequate	quantity[29]	new[29]	_	_
5-22	602-610	quantity	quantity[29]	new[29]	_	_
5-23	611-613	of	quantity[29]	new[29]	_	_
5-24	614-625	homogeneous	quantity[29]|object[30]	new[29]|giv[30]	coref	6-18[40_30]
5-25	626-631	cells	quantity[29]|object[30]	new[29]|giv[30]	_	_
5-26	632-633	.	_	_	_	_

#Text=Current induction strategies include embryonic bodies ( EB ) generation , differentiation on monolayers and co-culture with primary cells (
6-1	634-641	Current	abstract[32]	new[32]	_	_
6-2	642-651	induction	abstract|abstract[32]	giv|new[32]	coref	14-8[83_0]
6-3	652-662	strategies	abstract[32]	new[32]	_	_
6-4	663-670	include	_	_	_	_
6-5	671-680	embryonic	object[33]	new[33]	appos	6-7[36_33]
6-6	681-687	bodies	object[33]	new[33]	_	_
6-7	688-689	(	person[35]|object[36]	new[35]|giv[36]	_	_
6-8	690-692	EB	object|person[35]|object[36]	new|new[35]|giv[36]	coref	9-12
6-9	693-694	)	person[35]|object[36]	new[35]|giv[36]	_	_
6-10	695-705	generation	person[35]|object[36]	new[35]|giv[36]	_	_
6-11	706-707	,	object[36]	giv[36]	_	_
6-12	708-723	differentiation	object[36]|event[37]	giv[36]|giv[37]	coref	11-21[0_37]
6-13	724-726	on	object[36]|event[37]	giv[36]|giv[37]	_	_
6-14	727-737	monolayers	object[36]|event[37]|object	giv[36]|giv[37]|new	_	_
6-15	738-741	and	object[36]|event[37]	giv[36]|giv[37]	_	_
6-16	742-752	co-culture	object[36]|event[37]|abstract[39]	giv[36]|giv[37]|new[39]	coref	12-4[66_39]
6-17	753-757	with	object[36]|event[37]|abstract[39]	giv[36]|giv[37]|new[39]	_	_
6-18	758-765	primary	object[36]|event[37]|abstract[39]|object[40]	giv[36]|giv[37]|new[39]|giv[40]	coref	10-21[54_40]
6-19	766-771	cells	object[36]|event[37]|abstract[39]|object[40]	giv[36]|giv[37]|new[39]|giv[40]	_	_
6-20	772-773	(	_	_	_	_

#Text=Figure 4
7-1	774-780	Figure	abstract[41]	new[41]	_	_
7-2	781-782	4	abstract[41]	new[41]	_	_

#Text=) .
8-1	783-784	)	_	_	_	_
8-2	785-786	.	_	_	_	_

#Text=IPSCs tend to self-assemble into three-dimensional ( 3D ) structures ( EB ) when grown in suspension .
9-1	787-792	IPSCs	object	new	_	_
9-2	793-797	tend	_	_	_	_
9-3	798-800	to	_	_	_	_
9-4	801-814	self-assemble	_	_	_	_
9-5	815-819	into	_	_	_	_
9-6	820-837	three-dimensional	abstract[44]	new[44]	coref	10-26[55_44]
9-7	838-839	(	abstract[44]	new[44]	_	_
9-8	840-842	3D	abstract|abstract[44]	new|new[44]	_	_
9-9	843-844	)	abstract[44]	new[44]	_	_
9-10	845-855	structures	abstract[44]	new[44]	_	_
9-11	856-857	(	_	_	_	_
9-12	858-860	EB	place	giv	coref	10-21
9-13	861-862	)	_	_	_	_
9-14	863-867	when	_	_	_	_
9-15	868-873	grown	_	_	_	_
9-16	874-876	in	_	_	_	_
9-17	877-887	suspension	substance	new	_	_
9-18	888-889	.	_	_	_	_

#Text=From EBs , cell aggregates encompassing all three germ layers develop , and afterwards , within the positive mesodermal , EB cells tend to form vascular structures .
10-1	890-894	From	_	_	_	_
10-2	895-898	EBs	object	new	_	_
10-3	899-900	,	_	_	_	_
10-4	901-905	cell	place|abstract[49]	new|new[49]	coref|coref	12-8|12-8
10-5	906-916	aggregates	abstract[49]	new[49]	_	_
10-6	917-929	encompassing	_	_	_	_
10-7	930-933	all	abstract[51]	new[51]	_	_
10-8	934-939	three	abstract[51]	new[51]	_	_
10-9	940-944	germ	substance|abstract[51]	new|new[51]	_	_
10-10	945-951	layers	abstract[51]	new[51]	_	_
10-11	952-959	develop	_	_	_	_
10-12	960-961	,	_	_	_	_
10-13	962-965	and	_	_	_	_
10-14	966-976	afterwards	_	_	_	_
10-15	977-978	,	_	_	_	_
10-16	979-985	within	_	_	_	_
10-17	986-989	the	object[52]	new[52]	coref	23-6[0_52]
10-18	990-998	positive	object[52]	new[52]	_	_
10-19	999-1009	mesodermal	object[52]	new[52]	_	_
10-20	1010-1011	,	_	_	_	_
10-21	1012-1014	EB	substance|object[54]	giv|giv[54]	coref|coref	14-5[82_54]|14-5[82_54]
10-22	1015-1020	cells	object[54]	giv[54]	_	_
10-23	1021-1025	tend	_	_	_	_
10-24	1026-1028	to	_	_	_	_
10-25	1029-1033	form	_	_	_	_
10-26	1034-1042	vascular	abstract[55]	giv[55]	_	_
10-27	1043-1053	structures	abstract[55]	giv[55]	_	_
10-28	1054-1055	.	_	_	_	_

#Text=This method is affected by low efficiency ( 1 – 5 % ) and slow production rate ; however , differentiation can be improved by adding proper growth factors to the culture medium .
11-1	1056-1060	This	abstract[56]	new[56]	_	_
11-2	1061-1067	method	abstract[56]	new[56]	_	_
11-3	1068-1070	is	_	_	_	_
11-4	1071-1079	affected	_	_	_	_
11-5	1080-1082	by	_	_	_	_
11-6	1083-1086	low	abstract[57]	new[57]	_	_
11-7	1087-1097	efficiency	abstract[57]	new[57]	_	_
11-8	1098-1099	(	_	_	_	_
11-9	1100-1101	1	quantity[58]	new[58]	coref	21-25[0_58]
11-10	1102-1103	–	quantity[58]	new[58]	_	_
11-11	1104-1105	5	quantity[58]	new[58]	_	_
11-12	1106-1107	%	quantity[58]	new[58]	_	_
11-13	1108-1109	)	_	_	_	_
11-14	1110-1113	and	_	_	_	_
11-15	1114-1118	slow	abstract[60]	new[60]	_	_
11-16	1119-1129	production	abstract|abstract[60]	new|new[60]	coref	21-9[149_0]
11-17	1130-1134	rate	abstract[60]	new[60]	_	_
11-18	1135-1136	;	_	_	_	_
11-19	1137-1144	however	_	_	_	_
11-20	1145-1146	,	_	_	_	_
11-21	1147-1162	differentiation	event	giv	coref	12-13[70_0]
11-22	1163-1166	can	_	_	_	_
11-23	1167-1169	be	_	_	_	_
11-24	1170-1178	improved	_	_	_	_
11-25	1179-1181	by	_	_	_	_
11-26	1182-1188	adding	_	_	_	_
11-27	1189-1195	proper	abstract[63]	new[63]	coref	15-11[88_63]
11-28	1196-1202	growth	abstract|abstract[63]	new|new[63]	_	_
11-29	1203-1210	factors	abstract[63]	new[63]	_	_
11-30	1211-1213	to	abstract[63]	new[63]	_	_
11-31	1214-1217	the	abstract[63]|abstract[64]	new[63]|new[64]	coref	16-23[0_64]
11-32	1218-1225	culture	abstract[63]|abstract[64]	new[63]|new[64]	_	_
11-33	1226-1232	medium	abstract[63]|abstract[64]	new[63]|new[64]	_	_
11-34	1233-1234	.	_	_	_	_

#Text=Another approach involves a co-culture with primary cell lines able to induce iPSC-EC differentiation toward mature ECs .
12-1	1235-1242	Another	abstract[65]	new[65]	_	_
12-2	1243-1251	approach	abstract[65]	new[65]	_	_
12-3	1252-1260	involves	_	_	_	_
12-4	1261-1262	a	abstract[66]	giv[66]	_	_
12-5	1263-1273	co-culture	abstract[66]	giv[66]	_	_
12-6	1274-1278	with	abstract[66]	giv[66]	_	_
12-7	1279-1286	primary	abstract[66]|object[68]	giv[66]|new[68]	_	_
12-8	1287-1291	cell	abstract[66]|place|object[68]	giv[66]|giv|new[68]	coref	13-23
12-9	1292-1297	lines	abstract[66]|object[68]	giv[66]|new[68]	_	_
12-10	1298-1302	able	abstract[66]|object[68]	giv[66]|new[68]	_	_
12-11	1303-1305	to	abstract[66]|object[68]	giv[66]|new[68]	_	_
12-12	1306-1312	induce	abstract[66]|object[68]	giv[66]|new[68]	_	_
12-13	1313-1320	iPSC-EC	abstract[66]|object[68]|abstract|event[70]	giv[66]|new[68]|new|giv[70]	coref|coref	15-1[86_70]|15-1[86_70]
12-14	1321-1336	differentiation	abstract[66]|object[68]|event[70]	giv[66]|new[68]|giv[70]	_	_
12-15	1337-1343	toward	_	_	_	_
12-16	1344-1350	mature	object[71]	new[71]	coref	13-10[74_71]
12-17	1351-1354	ECs	object[71]	new[71]	_	_
12-18	1355-1356	.	_	_	_	_

#Text=In detail , Choi et al. directed hiPSCs into mature ECs in the presence of OP9 , a mouse bone marrow stromal cell line .
13-1	1357-1359	In	_	_	_	_
13-2	1360-1366	detail	_	_	_	_
13-3	1367-1368	,	_	_	_	_
13-4	1369-1373	Choi	person	new	_	_
13-5	1374-1376	et	_	_	_	_
13-6	1377-1380	al.	_	_	_	_
13-7	1381-1389	directed	_	_	_	_
13-8	1390-1396	hiPSCs	abstract	new	coref	16-19[98_0]
13-9	1397-1401	into	_	_	_	_
13-10	1402-1408	mature	object[74]	giv[74]	coref	17-25[118_74]
13-11	1409-1412	ECs	object[74]	giv[74]	_	_
13-12	1413-1415	in	_	_	_	_
13-13	1416-1419	the	abstract[75]	new[75]	_	_
13-14	1420-1428	presence	abstract[75]	new[75]	_	_
13-15	1429-1431	of	abstract[75]	new[75]	_	_
13-16	1432-1435	OP9	abstract[75]|object	new[75]|new	appos	13-18[80_0]
13-17	1436-1437	,	_	_	_	_
13-18	1438-1439	a	object[80]	giv[80]	_	_
13-19	1440-1445	mouse	object[80]	giv[80]	_	_
13-20	1446-1450	bone	object[80]	giv[80]	_	_
13-21	1451-1457	marrow	animal|object[80]	new|giv[80]	_	_
13-22	1458-1465	stromal	animal|object[80]	new|giv[80]	_	_
13-23	1466-1470	cell	object|object[80]	giv|giv[80]	coref	30-22
13-24	1471-1475	line	object[80]	giv[80]	_	_
13-25	1476-1477	.	_	_	_	_

#Text=The authors speculated that these cells regulate iPSC induction via a paracrine signaling .
14-1	1478-1481	The	person[81]	new[81]	ana	16-28[101_81]
14-2	1482-1489	authors	person[81]	new[81]	_	_
14-3	1490-1500	speculated	_	_	_	_
14-4	1501-1505	that	_	_	_	_
14-5	1506-1511	these	object[82]	giv[82]	coref	17-22[117_82]
14-6	1512-1517	cells	object[82]	giv[82]	_	_
14-7	1518-1526	regulate	_	_	_	_
14-8	1527-1531	iPSC	abstract[83]	giv[83]	coref	22-3[155_83]
14-9	1532-1541	induction	abstract[83]	giv[83]	_	_
14-10	1542-1545	via	_	_	_	_
14-11	1546-1547	a	abstract[84]	new[84]	coref	19-5[125_84]
14-12	1548-1557	paracrine	abstract[84]	new[84]	_	_
14-13	1558-1567	signaling	abstract[84]	new[84]	_	_
14-14	1568-1569	.	_	_	_	_

#Text=Monolayer differentiation holds a significantly higher efficiency that depends on external factors , such as medium constituents , showing a final yield that is still too low in the view of clinical applications .
15-1	1570-1579	Monolayer	person|event[86]	new|giv[86]	coref|coref	16-43[106_86]|16-43[106_86]
15-2	1580-1595	differentiation	event[86]	giv[86]	_	_
15-3	1596-1601	holds	_	_	_	_
15-4	1602-1603	a	abstract[87]	new[87]	coref	21-24[154_87]
15-5	1604-1617	significantly	abstract[87]	new[87]	_	_
15-6	1618-1624	higher	abstract[87]	new[87]	_	_
15-7	1625-1635	efficiency	abstract[87]	new[87]	_	_
15-8	1636-1640	that	_	_	_	_
15-9	1641-1648	depends	_	_	_	_
15-10	1649-1651	on	_	_	_	_
15-11	1652-1660	external	abstract[88]	giv[88]	coref	16-33[104_88]
15-12	1661-1668	factors	abstract[88]	giv[88]	_	_
15-13	1669-1670	,	abstract[88]	giv[88]	_	_
15-14	1671-1675	such	abstract[88]	giv[88]	_	_
15-15	1676-1678	as	abstract[88]	giv[88]	_	_
15-16	1679-1685	medium	abstract[88]|substance[89]	giv[88]|new[89]	_	_
15-17	1686-1698	constituents	abstract[88]|substance[89]	giv[88]|new[89]	_	_
15-18	1699-1700	,	_	_	_	_
15-19	1701-1708	showing	_	_	_	_
15-20	1709-1710	a	abstract[90]	new[90]	_	_
15-21	1711-1716	final	abstract[90]	new[90]	_	_
15-22	1717-1722	yield	abstract[90]	new[90]	_	_
15-23	1723-1727	that	_	_	_	_
15-24	1728-1730	is	_	_	_	_
15-25	1731-1736	still	_	_	_	_
15-26	1737-1740	too	_	_	_	_
15-27	1741-1744	low	_	_	_	_
15-28	1745-1747	in	_	_	_	_
15-29	1748-1751	the	abstract[91]	new[91]	coref	20-2[128_91]
15-30	1752-1756	view	abstract[91]	new[91]	_	_
15-31	1757-1759	of	abstract[91]	new[91]	_	_
15-32	1760-1768	clinical	abstract[91]|abstract[92]	new[91]|new[92]	_	_
15-33	1769-1781	applications	abstract[91]|abstract[92]	new[91]|new[92]	_	_
15-34	1782-1783	.	_	_	_	_

#Text=To date , the best protocols showing the highest EC yields were developed by culturing a monolayer of hiPSCs on a matrix-coated culture plate and by treating them with different molecules or growth factors in a timed fashion in order to guide the progressive differentiation of hiPSCs toward the EC lineage .
16-1	1784-1786	To	_	_	_	_
16-2	1787-1791	date	time	new	_	_
16-3	1792-1793	,	_	_	_	_
16-4	1794-1797	the	abstract[94]	giv[94]	_	_
16-5	1798-1802	best	abstract[94]	giv[94]	_	_
16-6	1803-1812	protocols	abstract[94]	giv[94]	_	_
16-7	1813-1820	showing	_	_	_	_
16-8	1821-1824	the	quantity[96]	new[96]	_	_
16-9	1825-1832	highest	quantity[96]	new[96]	_	_
16-10	1833-1835	EC	organization|quantity[96]	giv|new[96]	coref	16-50
16-11	1836-1842	yields	quantity[96]	new[96]	_	_
16-12	1843-1847	were	_	_	_	_
16-13	1848-1857	developed	_	_	_	_
16-14	1858-1860	by	_	_	_	_
16-15	1861-1870	culturing	_	_	_	_
16-16	1871-1872	a	object[97]	new[97]	_	_
16-17	1873-1882	monolayer	object[97]	new[97]	_	_
16-18	1883-1885	of	object[97]	new[97]	_	_
16-19	1886-1892	hiPSCs	object[97]|abstract[98]	new[97]|giv[98]	coref	16-47[0_98]
16-20	1893-1895	on	object[97]|abstract[98]	new[97]|giv[98]	_	_
16-21	1896-1897	a	object[97]|abstract[98]|object[100]	new[97]|giv[98]|new[100]	_	_
16-22	1898-1911	matrix-coated	object[97]|abstract[98]|object[100]	new[97]|giv[98]|new[100]	_	_
16-23	1912-1919	culture	object[97]|abstract[98]|abstract|object[100]	new[97]|giv[98]|giv|new[100]	_	_
16-24	1920-1925	plate	object[97]|abstract[98]|object[100]	new[97]|giv[98]|new[100]	_	_
16-25	1926-1929	and	_	_	_	_
16-26	1930-1932	by	_	_	_	_
16-27	1933-1941	treating	_	_	_	_
16-28	1942-1946	them	person[101]	giv[101]	coref	20-6[129_101]
16-29	1947-1951	with	person[101]	giv[101]	_	_
16-30	1952-1961	different	person[101]|substance[102]|abstract[103]	giv[101]|new[102]|new[103]	coref|coref|coref|coref	17-15[115_102]|21-4[148_103]|17-15[115_102]|21-4[148_103]
16-31	1962-1971	molecules	person[101]|substance[102]|abstract[103]	giv[101]|new[102]|new[103]	_	_
16-32	1972-1974	or	person[101]|abstract[103]	giv[101]|new[103]	_	_
16-33	1975-1981	growth	person[101]|abstract[103]|abstract[104]	giv[101]|new[103]|giv[104]	coref	23-13[0_104]
16-34	1982-1989	factors	person[101]|abstract[103]|abstract[104]	giv[101]|new[103]|giv[104]	_	_
16-35	1990-1992	in	person[101]|abstract[103]|abstract[104]	giv[101]|new[103]|giv[104]	_	_
16-36	1993-1994	a	person[101]|abstract[103]|abstract[104]|abstract[105]	giv[101]|new[103]|giv[104]|new[105]	_	_
16-37	1995-2000	timed	person[101]|abstract[103]|abstract[104]|abstract[105]	giv[101]|new[103]|giv[104]|new[105]	_	_
16-38	2001-2008	fashion	person[101]|abstract[103]|abstract[104]|abstract[105]	giv[101]|new[103]|giv[104]|new[105]	_	_
16-39	2009-2011	in	_	_	_	_
16-40	2012-2017	order	_	_	_	_
16-41	2018-2020	to	_	_	_	_
16-42	2021-2026	guide	_	_	_	_
16-43	2027-2030	the	event[106]	giv[106]	_	_
16-44	2031-2042	progressive	event[106]	giv[106]	_	_
16-45	2043-2058	differentiation	event[106]	giv[106]	_	_
16-46	2059-2061	of	event[106]	giv[106]	_	_
16-47	2062-2068	hiPSCs	event[106]|object	giv[106]|giv	coref	20-14
16-48	2069-2075	toward	_	_	_	_
16-49	2076-2079	the	abstract[109]	new[109]	_	_
16-50	2080-2082	EC	organization|abstract[109]	giv|new[109]	_	_
16-51	2083-2090	lineage	abstract[109]	new[109]	_	_
16-52	2091-2092	.	_	_	_	_

#Text=In this context , GSK3 inhibitors play an important role among the set of molecules necessary to induce the differentiation of pluripotent cells into mature ECs .
17-1	2093-2095	In	_	_	_	_
17-2	2096-2100	this	abstract[110]	new[110]	_	_
17-3	2101-2108	context	abstract[110]	new[110]	_	_
17-4	2109-2110	,	_	_	_	_
17-5	2111-2115	GSK3	abstract|abstract[112]	new|new[112]	coref|coref|coref|coref	19-12|20-10[131_112]|19-12|20-10[131_112]
17-6	2116-2126	inhibitors	abstract[112]	new[112]	_	_
17-7	2127-2131	play	_	_	_	_
17-8	2132-2134	an	abstract[113]	new[113]	_	_
17-9	2135-2144	important	abstract[113]	new[113]	_	_
17-10	2145-2149	role	abstract[113]	new[113]	_	_
17-11	2150-2155	among	abstract[113]	new[113]	_	_
17-12	2156-2159	the	abstract[113]|abstract[114]	new[113]|new[114]	_	_
17-13	2160-2163	set	abstract[113]|abstract[114]	new[113]|new[114]	_	_
17-14	2164-2166	of	abstract[113]|abstract[114]	new[113]|new[114]	_	_
17-15	2167-2176	molecules	abstract[113]|abstract[114]|substance[115]	new[113]|new[114]|giv[115]	_	_
17-16	2177-2186	necessary	abstract[113]|abstract[114]|substance[115]	new[113]|new[114]|giv[115]	_	_
17-17	2187-2189	to	abstract[113]|abstract[114]|substance[115]	new[113]|new[114]|giv[115]	_	_
17-18	2190-2196	induce	abstract[113]|abstract[114]|substance[115]	new[113]|new[114]|giv[115]	_	_
17-19	2197-2200	the	abstract[113]|abstract[114]|substance[115]|event[116]	new[113]|new[114]|giv[115]|new[116]	coref	22-11[0_116]
17-20	2201-2216	differentiation	abstract[113]|abstract[114]|substance[115]|event[116]	new[113]|new[114]|giv[115]|new[116]	_	_
17-21	2217-2219	of	abstract[113]|abstract[114]|substance[115]|event[116]	new[113]|new[114]|giv[115]|new[116]	_	_
17-22	2220-2231	pluripotent	abstract[113]|abstract[114]|substance[115]|event[116]|object[117]	new[113]|new[114]|giv[115]|new[116]|giv[117]	coref	23-10[161_117]
17-23	2232-2237	cells	abstract[113]|abstract[114]|substance[115]|event[116]|object[117]	new[113]|new[114]|giv[115]|new[116]|giv[117]	_	_
17-24	2238-2242	into	abstract[113]|abstract[114]|substance[115]|event[116]|object[117]	new[113]|new[114]|giv[115]|new[116]|giv[117]	_	_
17-25	2243-2249	mature	abstract[113]|abstract[114]|substance[115]|event[116]|object[117]|object[118]	new[113]|new[114]|giv[115]|new[116]|giv[117]|giv[118]	coref	20-16[0_118]
17-26	2250-2253	ECs	abstract[113]|abstract[114]|substance[115]|event[116]|object[117]|object[118]	new[113]|new[114]|giv[115]|new[116]|giv[117]|giv[118]	_	_
17-27	2254-2255	.	_	_	_	_

#Text=In particular , vascular progenitors derive during human development from latero-posterior mesoderm .
18-1	2256-2258	In	_	_	_	_
18-2	2259-2269	particular	_	_	_	_
18-3	2270-2271	,	_	_	_	_
18-4	2272-2280	vascular	abstract[119]	new[119]	_	_
18-5	2281-2292	progenitors	abstract[119]	new[119]	_	_
18-6	2293-2299	derive	_	_	_	_
18-7	2300-2306	during	_	_	_	_
18-8	2307-2312	human	abstract[120]	giv[120]	_	_
18-9	2313-2324	development	abstract[120]	giv[120]	_	_
18-10	2325-2329	from	abstract[120]	giv[120]	_	_
18-11	2330-2346	latero-posterior	abstract[120]|abstract|object[122]	giv[120]|new|new[122]	coref|coref	19-3[0_122]|19-3[0_122]
18-12	2347-2355	mesoderm	abstract[120]|object[122]	giv[120]|new[122]	_	_
18-13	2356-2357	.	_	_	_	_

#Text=To specify mesoderm , Wnt signaling , which is activated by GSK3 inhibition , is required .
19-1	2358-2360	To	_	_	_	_
19-2	2361-2368	specify	_	_	_	_
19-3	2369-2377	mesoderm	object	giv	coref	20-35
19-4	2378-2379	,	_	_	_	_
19-5	2380-2383	Wnt	abstract|abstract[125]	new|giv[125]	_	_
19-6	2384-2393	signaling	abstract[125]	giv[125]	_	_
19-7	2394-2395	,	_	_	_	_
19-8	2396-2401	which	_	_	_	_
19-9	2402-2404	is	_	_	_	_
19-10	2405-2414	activated	_	_	_	_
19-11	2415-2417	by	_	_	_	_
19-12	2418-2422	GSK3	abstract|abstract[127]	giv|new[127]	coref|coref	20-10|20-10
19-13	2423-2433	inhibition	abstract[127]	new[127]	_	_
19-14	2434-2435	,	_	_	_	_
19-15	2436-2438	is	_	_	_	_
19-16	2439-2447	required	_	_	_	_
19-17	2448-2449	.	_	_	_	_

#Text=In view of this , several authors have exploited GSK3 inhibitors to differentiate hiPSCs into ECs . Patsch et al. exposed a monolayer of hiPSC to GSK3 inhibitor CHIR-99021 ( CHIR ) and to mesoderm inducer bone morphogenetic protein 4 ( BMP4 ) .
20-1	2450-2452	In	_	_	_	_
20-2	2453-2457	view	abstract[128]	giv[128]	_	_
20-3	2458-2460	of	abstract[128]	giv[128]	_	_
20-4	2461-2465	this	abstract[128]	giv[128]	_	_
20-5	2466-2467	,	_	_	_	_
20-6	2468-2475	several	person[129]	giv[129]	_	_
20-7	2476-2483	authors	person[129]	giv[129]	_	_
20-8	2484-2488	have	_	_	_	_
20-9	2489-2498	exploited	_	_	_	_
20-10	2499-2503	GSK3	abstract|abstract[131]	giv|giv[131]	coref|coref	20-27|20-27
20-11	2504-2514	inhibitors	abstract[131]	giv[131]	_	_
20-12	2515-2517	to	_	_	_	_
20-13	2518-2531	differentiate	_	_	_	_
20-14	2532-2538	hiPSCs	abstract	giv	coref	26-20
20-15	2539-2543	into	_	_	_	_
20-16	2544-2547	ECs	object	giv	coref	21-12[150_0]
20-17	2548-2549	.	_	_	_	_
20-18	2550-2556	Patsch	person	new	_	_
20-19	2557-2559	et	_	_	_	_
20-20	2560-2563	al.	_	_	_	_
20-21	2564-2571	exposed	_	_	_	_
20-22	2572-2573	a	object[135]	new[135]	_	_
20-23	2574-2583	monolayer	object[135]	new[135]	_	_
20-24	2584-2586	of	object[135]	new[135]	_	_
20-25	2587-2592	hiPSC	object[135]|object	new[135]|new	_	_
20-26	2593-2595	to	_	_	_	_
20-27	2596-2600	GSK3	abstract|object[138]|object[139]	giv|new[138]|new[139]	appos|appos|appos	20-31[0_139]|20-31[0_139]|20-31[0_139]
20-28	2601-2610	inhibitor	object[138]|object[139]	new[138]|new[139]	_	_
20-29	2611-2621	CHIR-99021	object[139]	new[139]	_	_
20-30	2622-2623	(	_	_	_	_
20-31	2624-2628	CHIR	object	giv	_	_
20-32	2629-2630	)	_	_	_	_
20-33	2631-2634	and	_	_	_	_
20-34	2635-2637	to	_	_	_	_
20-35	2638-2646	mesoderm	object|object[143]|abstract[145]	giv|new[143]|new[145]	appos|appos|appos	20-42[0_145]|20-42[0_145]|20-42[0_145]
20-36	2647-2654	inducer	person|object[143]|abstract[145]	new|new[143]|new[145]	_	_
20-37	2655-2659	bone	object[143]|abstract[145]	new[143]|new[145]	_	_
20-38	2660-2673	morphogenetic	abstract|abstract[145]	new|new[145]	_	_
20-39	2674-2681	protein	abstract[145]	new[145]	_	_
20-40	2682-2683	4	abstract[145]	new[145]	_	_
20-41	2684-2685	(	_	_	_	_
20-42	2686-2690	BMP4	abstract	giv	coref	26-9
20-43	2691-2692	)	_	_	_	_
20-44	2693-2694	.	_	_	_	_

#Text=The combination of these two molecules led to the production of mature ECs in a relatively short time ( six days ) with 80 % efficiency .
21-1	2695-2698	The	abstract[147]	new[147]	_	_
21-2	2699-2710	combination	abstract[147]	new[147]	_	_
21-3	2711-2713	of	abstract[147]	new[147]	_	_
21-4	2714-2719	these	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
21-5	2720-2723	two	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
21-6	2724-2733	molecules	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
21-7	2734-2737	led	_	_	_	_
21-8	2738-2740	to	_	_	_	_
21-9	2741-2744	the	abstract[149]	giv[149]	_	_
21-10	2745-2755	production	abstract[149]	giv[149]	_	_
21-11	2756-2758	of	abstract[149]	giv[149]	_	_
21-12	2759-2765	mature	abstract[149]|object[150]	giv[149]|giv[150]	coref	24-21[171_150]
21-13	2766-2769	ECs	abstract[149]|object[150]	giv[149]|giv[150]	_	_
21-14	2770-2772	in	_	_	_	_
21-15	2773-2774	a	time[151]	new[151]	appos	21-20[152_151]
21-16	2775-2785	relatively	time[151]	new[151]	_	_
21-17	2786-2791	short	time[151]	new[151]	_	_
21-18	2792-2796	time	time[151]	new[151]	_	_
21-19	2797-2798	(	_	_	_	_
21-20	2799-2802	six	time[152]	giv[152]	_	_
21-21	2803-2807	days	time[152]	giv[152]	_	_
21-22	2808-2809	)	_	_	_	_
21-23	2810-2814	with	_	_	_	_
21-24	2815-2817	80	abstract[154]	giv[154]	_	_
21-25	2818-2819	%	quantity|abstract[154]	giv|giv[154]	_	_
21-26	2820-2830	efficiency	abstract[154]	giv[154]	_	_
21-27	2831-2832	.	_	_	_	_

#Text=However , mesoderm induction is only the first step of differentiation .
22-1	2833-2840	However	_	_	_	_
22-2	2841-2842	,	_	_	_	_
22-3	2843-2851	mesoderm	abstract[155]	giv[155]	coref	22-6[156_155]
22-4	2852-2861	induction	abstract[155]	giv[155]	_	_
22-5	2862-2864	is	_	_	_	_
22-6	2865-2869	only	abstract[156]	giv[156]	_	_
22-7	2870-2873	the	abstract[156]	giv[156]	_	_
22-8	2874-2879	first	abstract[156]	giv[156]	_	_
22-9	2880-2884	step	abstract[156]	giv[156]	_	_
22-10	2885-2887	of	abstract[156]	giv[156]	_	_
22-11	2888-2903	differentiation	abstract[156]|event	giv[156]|giv	coref	28-17
22-12	2904-2905	.	_	_	_	_

#Text=The second part starts upon mesodermal commitment by exposing the cells to factors that further induce the mature vascular phenotype .
23-1	2906-2909	The	abstract[158]	new[158]	_	_
23-2	2910-2916	second	abstract[158]	new[158]	_	_
23-3	2917-2921	part	abstract[158]	new[158]	_	_
23-4	2922-2928	starts	_	_	_	_
23-5	2929-2933	upon	_	_	_	_
23-6	2934-2944	mesodermal	object|event[160]	giv|new[160]	_	_
23-7	2945-2955	commitment	event[160]	new[160]	_	_
23-8	2956-2958	by	_	_	_	_
23-9	2959-2967	exposing	_	_	_	_
23-10	2968-2971	the	object[161]	giv[161]	coref	25-1[173_161]
23-11	2972-2977	cells	object[161]	giv[161]	_	_
23-12	2978-2980	to	_	_	_	_
23-13	2981-2988	factors	abstract	giv	_	_
23-14	2989-2993	that	_	_	_	_
23-15	2994-3001	further	_	_	_	_
23-16	3002-3008	induce	_	_	_	_
23-17	3009-3012	the	abstract[163]	new[163]	_	_
23-18	3013-3019	mature	abstract[163]	new[163]	_	_
23-19	3020-3028	vascular	abstract[163]	new[163]	_	_
23-20	3029-3038	phenotype	abstract[163]	new[163]	_	_
23-21	3039-3040	.	_	_	_	_

#Text=Gu set up a protocol through which , after 4 days of treatment with VEGF and bFGF , he produced mature ECs in only 8 days .
24-1	3041-3043	Gu	person	new	ana	24-19
24-2	3044-3047	set	_	_	_	_
24-3	3048-3050	up	_	_	_	_
24-4	3051-3052	a	abstract[165]	giv[165]	coref	26-11[179_165]
24-5	3053-3061	protocol	abstract[165]	giv[165]	_	_
24-6	3062-3069	through	_	_	_	_
24-7	3070-3075	which	_	_	_	_
24-8	3076-3077	,	_	_	_	_
24-9	3078-3083	after	_	_	_	_
24-10	3084-3085	4	time[166]	new[166]	_	_
24-11	3086-3090	days	time[166]	new[166]	_	_
24-12	3091-3093	of	time[166]	new[166]	_	_
24-13	3094-3103	treatment	time[166]|event	new[166]|new	_	_
24-14	3104-3108	with	time[166]	new[166]	_	_
24-15	3109-3113	VEGF	time[166]|substance	new[166]|new	coref	26-5
24-16	3114-3117	and	time[166]	new[166]	_	_
24-17	3118-3122	bFGF	time[166]|substance	new[166]|new	coref	26-7
24-18	3123-3124	,	_	_	_	_
24-19	3125-3127	he	person	giv	_	_
24-20	3128-3136	produced	_	_	_	_
24-21	3137-3143	mature	object[171]	giv[171]	coref	25-13[174_171]
24-22	3144-3147	ECs	object[171]	giv[171]	_	_
24-23	3148-3150	in	_	_	_	_
24-24	3151-3155	only	time[172]	new[172]	_	_
24-25	3156-3157	8	time[172]	new[172]	_	_
24-26	3158-3162	days	time[172]	new[172]	_	_
24-27	3163-3164	.	_	_	_	_

#Text=These cells , when tested , were molecularly and functionally similar to native ECs .
25-1	3165-3170	These	object[173]	giv[173]	coref	28-4[189_173]
25-2	3171-3176	cells	object[173]	giv[173]	_	_
25-3	3177-3178	,	_	_	_	_
25-4	3179-3183	when	_	_	_	_
25-5	3184-3190	tested	_	_	_	_
25-6	3191-3192	,	_	_	_	_
25-7	3193-3197	were	_	_	_	_
25-8	3198-3209	molecularly	_	_	_	_
25-9	3210-3213	and	_	_	_	_
25-10	3214-3226	functionally	_	_	_	_
25-11	3227-3234	similar	_	_	_	_
25-12	3235-3237	to	_	_	_	_
25-13	3238-3244	native	object[174]	giv[174]	coref	26-17[180_174]
25-14	3245-3248	ECs	object[174]	giv[174]	_	_
25-15	3249-3250	.	_	_	_	_

#Text=Paik et al. added VEGF , bFGF and BMP4 to an already established protocol to produce mature ECs from hiPSCs within 12 days .
26-1	3251-3255	Paik	person	new	_	_
26-2	3256-3258	et	_	_	_	_
26-3	3259-3262	al.	_	_	_	_
26-4	3263-3268	added	_	_	_	_
26-5	3269-3273	VEGF	substance	giv	_	_
26-6	3274-3275	,	_	_	_	_
26-7	3276-3280	bFGF	abstract	giv	_	_
26-8	3281-3284	and	_	_	_	_
26-9	3285-3289	BMP4	organization	giv	_	_
26-10	3290-3292	to	_	_	_	_
26-11	3293-3295	an	abstract[179]	giv[179]	coref	27-2[183_179]
26-12	3296-3303	already	abstract[179]	giv[179]	_	_
26-13	3304-3315	established	abstract[179]	giv[179]	_	_
26-14	3316-3324	protocol	abstract[179]	giv[179]	_	_
26-15	3325-3327	to	_	_	_	_
26-16	3328-3335	produce	_	_	_	_
26-17	3336-3342	mature	object[180]	giv[180]	_	_
26-18	3343-3346	ECs	object[180]	giv[180]	_	_
26-19	3347-3351	from	_	_	_	_
26-20	3352-3358	hiPSCs	object	giv	_	_
26-21	3359-3365	within	_	_	_	_
26-22	3366-3368	12	time[182]	new[182]	_	_
26-23	3369-3373	days	time[182]	new[182]	_	_
26-24	3374-3375	.	_	_	_	_

#Text=Although this protocol requires more time compared to other ones reported in literature , the aim of this study was different .
27-1	3376-3384	Although	_	_	_	_
27-2	3385-3389	this	abstract[183]	giv[183]	coref	29-6[196_183]
27-3	3390-3398	protocol	abstract[183]	giv[183]	_	_
27-4	3399-3407	requires	_	_	_	_
27-5	3408-3412	more	time[184]	new[184]	_	_
27-6	3413-3417	time	time[184]	new[184]	_	_
27-7	3418-3426	compared	_	_	_	_
27-8	3427-3429	to	_	_	_	_
27-9	3430-3435	other	object[185]	giv[185]	_	_
27-10	3436-3440	ones	object[185]	giv[185]	_	_
27-11	3441-3449	reported	_	_	_	_
27-12	3450-3452	in	_	_	_	_
27-13	3453-3463	literature	abstract	new	_	_
27-14	3464-3465	,	_	_	_	_
27-15	3466-3469	the	abstract[187]	new[187]	_	_
27-16	3470-3473	aim	abstract[187]	new[187]	_	_
27-17	3474-3476	of	abstract[187]	new[187]	_	_
27-18	3477-3481	this	abstract[187]|event[188]	new[187]|new[188]	_	_
27-19	3482-3487	study	abstract[187]|event[188]	new[187]|new[188]	_	_
27-20	3488-3491	was	_	_	_	_
27-21	3492-3501	different	_	_	_	_
27-22	3502-3503	.	_	_	_	_

#Text=In fact , these cells were used to draw an RNA signature at different stage of differentiation .
28-1	3504-3506	In	_	_	_	_
28-2	3507-3511	fact	_	_	_	_
28-3	3512-3513	,	_	_	_	_
28-4	3514-3519	these	object[189]	giv[189]	coref	29-13[198_189]
28-5	3520-3525	cells	object[189]	giv[189]	_	_
28-6	3526-3530	were	_	_	_	_
28-7	3531-3535	used	_	_	_	_
28-8	3536-3538	to	_	_	_	_
28-9	3539-3543	draw	_	_	_	_
28-10	3544-3546	an	abstract[191]	new[191]	_	_
28-11	3547-3550	RNA	organization|abstract[191]	new|new[191]	_	_
28-12	3551-3560	signature	abstract[191]	new[191]	_	_
28-13	3561-3563	at	_	_	_	_
28-14	3564-3573	different	abstract[192]	new[192]	_	_
28-15	3574-3579	stage	abstract[192]	new[192]	_	_
28-16	3580-3582	of	abstract[192]	new[192]	_	_
28-17	3583-3598	differentiation	abstract[192]|event	new[192]|giv	coref	29-7
28-18	3599-3600	.	_	_	_	_

#Text=The last step included in the differentiation protocol is the purification of positive cells .
29-1	3601-3604	The	abstract[194]	new[194]	coref	29-10[197_194]
29-2	3605-3609	last	abstract[194]	new[194]	_	_
29-3	3610-3614	step	abstract[194]	new[194]	_	_
29-4	3615-3623	included	_	_	_	_
29-5	3624-3626	in	_	_	_	_
29-6	3627-3630	the	abstract[196]	giv[196]	_	_
29-7	3631-3646	differentiation	event|abstract[196]	giv|giv[196]	_	_
29-8	3647-3655	protocol	abstract[196]	giv[196]	_	_
29-9	3656-3658	is	_	_	_	_
29-10	3659-3662	the	abstract[197]	giv[197]	coref	30-1[199_197]
29-11	3663-3675	purification	abstract[197]	giv[197]	_	_
29-12	3676-3678	of	abstract[197]	giv[197]	_	_
29-13	3679-3687	positive	abstract[197]|object[198]	giv[197]|giv[198]	coref	30-12[0_198]
29-14	3688-3693	cells	abstract[197]|object[198]	giv[197]|giv[198]	_	_
29-15	3694-3695	.	_	_	_	_

#Text=This step is essential to fish out a homogenous subset of cells and to ensure the safety needed for the future cell implantation and engraftment .
30-1	3696-3700	This	abstract[199]	giv[199]	_	_
30-2	3701-3705	step	abstract[199]	giv[199]	_	_
30-3	3706-3708	is	_	_	_	_
30-4	3709-3718	essential	_	_	_	_
30-5	3719-3721	to	_	_	_	_
30-6	3722-3726	fish	_	_	_	_
30-7	3727-3730	out	_	_	_	_
30-8	3731-3732	a	abstract[200]	new[200]	_	_
30-9	3733-3743	homogenous	abstract[200]	new[200]	_	_
30-10	3744-3750	subset	abstract[200]	new[200]	_	_
30-11	3751-3753	of	abstract[200]	new[200]	_	_
30-12	3754-3759	cells	abstract[200]|object	new[200]|giv	_	_
30-13	3760-3763	and	_	_	_	_
30-14	3764-3766	to	_	_	_	_
30-15	3767-3773	ensure	_	_	_	_
30-16	3774-3777	the	abstract[202]	new[202]	_	_
30-17	3778-3784	safety	abstract[202]	new[202]	_	_
30-18	3785-3791	needed	_	_	_	_
30-19	3792-3795	for	_	_	_	_
30-20	3796-3799	the	event[204]	new[204]	_	_
30-21	3800-3806	future	event[204]	new[204]	_	_
30-22	3807-3811	cell	place|event[204]	giv|new[204]	_	_
30-23	3812-3824	implantation	event[204]	new[204]	_	_
30-24	3825-3828	and	_	_	_	_
30-25	3829-3840	engraftment	event	new	_	_
30-26	3841-3842	.	_	_	_	_

#Text=Cell sorting is usually performed by using magnetic beads on which surface specific antibodies are adsorbed .
31-1	3843-3847	Cell	person|abstract[207]	new|new[207]	_	_
31-2	3848-3855	sorting	abstract[207]	new[207]	_	_
31-3	3856-3858	is	_	_	_	_
31-4	3859-3866	usually	_	_	_	_
31-5	3867-3876	performed	_	_	_	_
31-6	3877-3879	by	_	_	_	_
31-7	3880-3885	using	_	_	_	_
31-8	3886-3894	magnetic	object[208]	new[208]	_	_
31-9	3895-3900	beads	object[208]	new[208]	_	_
31-10	3901-3903	on	_	_	_	_
31-11	3904-3909	which	_	_	_	_
31-12	3910-3917	surface	place|substance[210]	new|new[210]	coref|coref	32-1[211_210]|32-1[211_210]
31-13	3918-3926	specific	substance[210]	new[210]	_	_
31-14	3927-3937	antibodies	substance[210]	new[210]	_	_
31-15	3938-3941	are	_	_	_	_
31-16	3942-3950	adsorbed	_	_	_	_
31-17	3951-3952	.	_	_	_	_

#Text=These antibodies are directed against mature endothelial markers such as CD31 or VE-cadherin ( also known as CD144 ) .
32-1	3953-3958	These	substance[211]	giv[211]	_	_
32-2	3959-3969	antibodies	substance[211]	giv[211]	_	_
32-3	3970-3973	are	_	_	_	_
32-4	3974-3982	directed	_	_	_	_
32-5	3983-3990	against	_	_	_	_
32-6	3991-3997	mature	abstract[213]	new[213]	_	_
32-7	3998-4009	endothelial	place|abstract[213]	new|new[213]	_	_
32-8	4010-4017	markers	abstract[213]	new[213]	_	_
32-9	4018-4022	such	abstract[213]	new[213]	_	_
32-10	4023-4025	as	abstract[213]	new[213]	_	_
32-11	4026-4030	CD31	abstract[213]|abstract	new[213]|new	_	_
32-12	4031-4033	or	abstract[213]	new[213]	_	_
32-13	4034-4045	VE-cadherin	abstract[213]|object	new[213]|new	_	_
32-14	4046-4047	(	_	_	_	_
32-15	4048-4052	also	_	_	_	_
32-16	4053-4058	known	_	_	_	_
32-17	4059-4061	as	_	_	_	_
32-18	4062-4067	CD144	_	_	_	_
32-19	4068-4069	)	_	_	_	_
32-20	4070-4071	.	_	_	_	_
